Loading...
Loading...
XBIT| Name | Value |
|---|---|
| Revenues | 300.0K |
| Cost of Revenue | 16.0K |
| Gross Profit | 284.0K |
| Operating Expense | 8,446.0K |
| Operating I/L | -8,162.0K |
| Other Income/Expense | 5,537.0K |
| Interest Income | 2,472.0K |
| Pretax | -2,625.0K |
| Income Tax Expense | 578.0K |
| Net Income/Loss | -3,203.0K |
XBiotech Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of True Human monoclonal antibodies for the treatment of inflammatory and infectious diseases. The company's product pipeline includes interleukin-1 alpha therapies targeting conditions such as cancer, stroke, heart attack, and arthritis, as well as True Human COVID-19 therapy for the treatment of the COVID-19 mutant virus. By focusing on the development of innovative therapies, XBiotech Inc. generates revenue through the sale and licensing of its proprietary antibody-based treatments for various medical conditions.
